市场调查报告书
商品编码
1497603
急性护理综合症检测市场:按疾病类型、目标、样本类型和最终用户 - 2024-2030 年全球预测Acute Care Syndromic Testing Market by Disease Type (Gastrointestinal Diseases, Genitourinary Diseases, Respiratory Diseases), Target (Bacteria, Fungi, Parasites), Sample Type, End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年急性医学症候群检测市场规模为34亿美元,预计2024年将达37.4亿美元,2030年将达66.3亿美元,复合年增长率为9.99%。
急性护理综合症测试是指在医疗机构中使用的快速诊断过程,透过同时测试多种可能的原因来确定有症状患者的临床症状的原因。即时聚合酵素链锁反应(PCR) 可用于定性检测和识别病毒、细菌、真菌和寄生虫病原体。这种方法在急诊室和加护病房等急诊护理环境中尤其重要,因为在这些环境中,即时决策至关重要。我们使用的测试组合涵盖了与特定临床综合征相关的病原体和病症,例如呼吸道疾病和胃肠道感染疾病。包括多重抗药性病原体在内的感染疾病的流行增加了对快速综合症检测的需求。此外,政府改善医疗基础设施和促进先进诊断系统采用的措施也促进了市场成长。然而,假阳性和阴性的发生率以及某些综合症测试缺乏足够的报销可能会阻碍急性护理综合症测试的采用。此外,技术挑战和检测有限数量微生物病原体的能力也是产业发展的障碍。然而,大公司正在寻求开发更广泛的组合,可以在一次测试中检测多种病原体。临床和医学微生物学的研究倡议和进展可以提高急性护理症候群测试工具的性能和准确性。此外,人工智慧/机器学习、资料分析技术和计算生物学策略等先进数位技术的整合可以为该行业提供新的成长途径。
主要市场统计 | |
---|---|
基准年[2023] | 34亿美元 |
预测年份 [2024] | 37.4亿美元 |
预测年份 [2030] | 66.3亿美元 |
复合年增长率(%) | 9.99% |
区域洞察
以美国和加拿大为中心的美洲地区拥有强大的医疗基础设施和数数位化医疗框架,极大地推动了医院和诊所采用急性护理综合症检测。在其他活动中,疾病管制与预防美国(CDC) 和其他联邦机构正在积极鼓励开发快速综合症检测方法。医疗支付者和医院是重要的客户,他们的购买行为反映了对能够快速提供结果并支持抗菌药物管理的全面解决方案的偏好。欧盟强调遵守与医疗保健产业相关的严格法规。此外,学术机构、主要企业和研究机构之间的密切合作正在推动诊断和综合征检测领域的创新和改进。抗菌素抗药性的增加也推动了对先进诊断工具的需求。在亚太地区,对医疗改革和政府倡议的日益关注以及扩大先进医疗服务和设施的资助是推动急性护理综合症检测采用的关键因素。来自韩国、印度和中国的参与者正在与诊断测试实验室合作,扩大急性护理症候群测试的普及。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在急性护理症候群测试市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对急性护理综合症检测市场中供应商的现状进行深入而详细的评估。对供应商贡献的彻底比较和分析可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在急性护理综合症检测市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[192 Pages Report] The Acute Care Syndromic Testing Market size was estimated at USD 3.40 billion in 2023 and expected to reach USD 3.74 billion in 2024, at a CAGR 9.99% to reach USD 6.63 billion by 2030.
Acute care syndromic testing refers to the rapid diagnostic process used in healthcare settings to identify the cause of a symptomatic patient's clinical symptoms by testing for multiple possible causes simultaneously. It facilitates qualitative detection and identification of viral, bacterial, fungal, and parasitic pathogens using real-time polymerase chain reaction (PCR). This approach is particularly significant in acute care settings where time-sensitive decisions are crucial, such as emergency departments or intensive care units. It employs panels of tests that cover a range of pathogens or conditions associated with a particular clinical syndrome, such as respiratory illness or gastrointestinal infection. The rise in infectious disease prevalence, including multi-drug-resistant pathogens, drives the need for rapid syndromic testing. Furthermore, government initiatives to improve medical infrastructure and stimulate the adoption of advanced diagnostics systems contribute to market growth. However, incidences of false positives and negatives and a lack of adequate reimbursements for certain syndromic tests can impede the adoption of acute care syndromic testing. Additionally, technical challenges and the ability to detect a limited number of microbial pathogens pose hurdles to the growth of the industry. However, key players are exploring the development of broader-ranging panels that can detect multiple pathogens in a single test. Research initiatives and advancements in clinical and medical microbiology can improve the performance and accuracy of acute care syndromic testing tools. Furthermore, the integration of advanced digital technologies such as AI/ML, data analysis technologies, and computational biology strategies can create new avenues of growth for the industry.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.40 billion |
Estimated Year [2024] | USD 3.74 billion |
Forecast Year [2030] | USD 6.63 billion |
CAGR (%) | 9.99% |
Regional Insights
The Americas region, particularly the US and Canada, boasts a robust healthcare infrastructure and digitalized healthcare framework, significantly driving the adoption of acute care syndromic testing in hospitals and clinics. Additionally, the Centers for Disease Control and Prevention (CDC) and other federal bodies actively encourage the development of rapid syndromic testing methods. Health insurers and hospitals are significant customers, and their purchasing behavior reflects a preference for integrated solutions that can provide quick results and aid in antimicrobial stewardship. The EU puts emphasis on compliance with stringent regulations pertaining to the healthcare sector. Additionally, strong collaborations between academic institutions, key players, and research institutes have led to innovations and improvements in the field of diagnostics and syndromic testing. Increasing antimicrobial resistance has also propelled the need for advanced diagnostics tools. In the APAC region, growing focus on healthcare reform and government initiatives and funds to expand access to advanced medical services and facilities are key factors leading to the adoption of acute care syndromic testing. Players in South Korea, India, and China are collaborating with diagnostic testing laboratories to expand the spread of acute care syndromic testing.
Market Insights
The market dynamics represent an ever-changing landscape of the Acute Care Syndromic Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acute Care Syndromic Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acute Care Syndromic Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Clears COVID-19 Home Antigen Test
The U.S. Food and Drug Administration (FDA) officially cleared ACON Laboratories' Flowflex COVID-19 Antigen Home Test for over-the-counter sales. This antigen test, which initially received Emergency Use Authorization in 2021, stands out as the second home diagnostic for COVID-19 to transition through a standard premarket evaluation by the FDA, marking a significant milestone. This development underscores the expansion of accessible testing options for the detection of COVID-19 for the public, including minors. [Published On: 2023-11-09]
Biden Government to Deliver Free COVID Tests To U.S. Households And Invest USD 600 Million In Domestic Manufacturers
The United States Department of Health and Human Services (HHS) confirmed its intent to combat the ongoing challenge posed by COVID-19 by providing American households with no-cost testing kits. The HHS has also unveiled an ambitious strategy, allocating USD 600 million to bolster the production capabilities of twelve domestic testing manufacturers, ensuring a robust response to the pandemic through the end of 2023. This strategic move underscores the continuing effort to keep citizens safe and well-informed amidst the evolving health crisis. [Published On: 2023-09-23]
NIH Launches Home Test to Treat a Pilot COVID-19 Telehealth Program
The U.S. National Institutes of Health, in partnership with the Administration for Strategic Preparedness and Response, has rolled out an innovative Home Test to Treat program, announced previously by the White House. This virtual community health initiative seeks to offer complimentary COVID-19 health amenities to designated communities, including at-home rapid tests, telehealth consultations, and treatment options. Through this program, individuals who test positive for COVID-19 using at-home tests are eligible to receive antiviral medications, enhancing their chances of averting serious illness, hospitalization, or death. [Published On: 2023-01-05]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acute Care Syndromic Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Acute Care Syndromic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Applied BioCode, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, BIOHM Health LLC, bioMerieux SA, Curetis GmbH b y OpGen, Inc, CVS Health, Danaher Corporation, DiaSorin S.p.A, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Genetic Signatures Ltd., Hologic Inc., Luminex Corporation, Microbiologics, Inc., Pfizer, Inc., QIAGEN N.V., QuantuMDx Group Ltd., Seegene Inc., Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Werfen.
Market Segmentation & Coverage